Minhu Chen

机构：Sun Yat-sen University, The First Affiliated Hospital, Sun Yat-sen University · ORCID：0000-0001-8181-0846

发表论文 50 篇 · 总被引 1166 次 · h-index 11

代表论文

• Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study (2024 · The Lancet · 被引 107)
• Multi‐Omics Biomarkers for Predicting Efficacy of Biologic and Small‐Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review (2024 · United European Gastroenterology Journal · 被引 26)
• Dual activation of GCGR/GLP1R signaling ameliorates intestinal fibrosis via metabolic regulation of histone H3K9 lactylation in epithelial cells (2024 · Acta Pharmaceutica Sinica B · 被引 20)
• Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends (2024 · Inflammatory Bowel Diseases · 被引 10)
• Efficacy and safety of intravenous vedolizumab treatment in Chinese patients with moderate-to-severe Crohn's disease (2025 · Clinics and Research in Hepatology and Gastroenterology · 被引 5)
• Fibroblast-derived interleukin-11 as a potential biomarker for intestinal fibrostenosis in Crohn’s disease (2025 · Therapeutic Advances in Gastroenterology · 被引 4)